Literature DB >> 12644842

Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.

Kara Lee Shirley1, Yuen Y Hon, Scott R Penzak, Y W Francis Lam, Vicky Spratlin, Michael W Jann.   

Abstract

Olanzapine has previously been shown to have predominant metabolism by cytochrome (CYP) P450 1A2. Caffeine has been shown to provide an accurate phenotypic probe for measuring CYP1A2 activity. The purpose of this study is to determine if a significant correlation exists between olanzapine disposition and caffeine metabolic ratios. Subjects were phenotyped for CYP1A2 activity with caffeine probe methodology. After 200-mg caffeine administration, blood (4 h), saliva (6 and 10 h), and urine (8 h total) were collected for high-performance liquid chromatography (HPLC) analysis of caffeine and its metabolites.CYP1A2 activity was measured as plasma (PMR(4 h)), saliva (SMR(6 h) and SMR(10 h)), and three urinary metabolic (UMR1(8 h), UMR2(8 h), and UMR3(8 h)) ratios. Each of the 14 healthy nonsmokers (13 male) received a single 10 mg olanzapine dose after which blood was collected for HPLC determination of olanzapine concentrations at predose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, and 120 h postdose. Olanzapine pharmacokinetic parameters in this study were similar to those previously published. All caffeine metabolic ratios (PMR(4 h), SMR(6 h), SMR(10 h), UMR1(8 h), and UMR2(8 h)) significantly correlated with each other (p <0.001) except for UMR3(8 h), which did not correlate. A significant correlation (p <0.05) was also found between olanzapine clearance and PMR(4 h) (r=0.701), SMR(6 h) (r=0.644), SMR(10 h) (r=0.701), UMR1(8 h) (r=0.745), and UMR2(8 h) (r=0.710). A negative correlation was observed between olanzapine clearance and UMR3(8 h) (r=-0.029, p=NS). A significant correlation was found between olanzapine clearance and various caffeine metabolic ratios. Interpatient variability in CYP1A2 activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may be expected to alter olanzapine pharmacokinetics accordingly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644842     DOI: 10.1038/sj.npp.1300123

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  9 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.

Authors:  Thu Thuy Nguyen; Henri Bénech; Alain Pruvost; Natacha Lenuzza
Journal:  Eur J Clin Pharmacol       Date:  2016-01       Impact factor: 2.953

Review 3.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

4.  The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.

Authors:  J A Arnaiz; C Rodrigues-Silva; G Mezquida; S Amoretti; M J Cuesta; D Fraguas; A Lobo; A González-Pinto; M C Díaz-Caneja; I Corripio; E Vieta; I Baeza; A Mané; C García-Rizo; M Bioque; J Saiz; M Bernardo; S Mas
Journal:  Psychopharmacology (Berl)       Date:  2020-11-23       Impact factor: 4.530

Review 5.  Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?

Authors:  Erin Schwenger; Jane Dumontet; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

6.  Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 7.  Clinical applications of CYP genotyping in psychiatry.

Authors:  Edoardo Spina; Jose de Leon
Journal:  J Neural Transm (Vienna)       Date:  2014-09-09       Impact factor: 3.575

8.  Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.

Authors:  Thomas M Polasek; Geoffrey T Tucker; Michael J Sorich; Michael D Wiese; Titus Mohan; Amin Rostami-Hodjegan; Porntipa Korprasertthaworn; Vidya Perera; Andrew Rowland
Journal:  Br J Clin Pharmacol       Date:  2018-01-11       Impact factor: 4.335

9.  Population pharmacokinetics of olanzapine in children.

Authors:  Anil R Maharaj; Huali Wu; Kanecia O Zimmerman; Julie Autmizguine; Rohit Kalra; Amira Al-Uzri; Catherine M T Sherwin; Stuart L Goldstein; Kevin Watt; Jinson Erinjeri; Elizabeth H Payne; Michael Cohen-Wolkowiez; Christoph P Hornik
Journal:  Br J Clin Pharmacol       Date:  2020-07-05       Impact factor: 3.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.